Contract Notice Detail

Summary Information

Summary Information
50,199.800000 Euro
 
 
61003123 
Aquisição de OCRElizumab 300 mg/10 ml Sol inj Fr 10 ml IV ao Abrigo do AQ 2021/6 
Tendering Phase
Awarded
10 frascos de OCRElizumab 300 mg/10 ml Sol inj Fr 10 ml IV  
VortalGOV - Acquisition under a Framework Agreement (via Direct Award) 
Lot NameLot Base PriceExpected Duration
O1030 - OCRELIZUMAB [300 MG/ 10 ML; SOL INJ; FRS]50,199.800000 Euro30 (Days)

Object of the Contract

Object of the Contract
Supplies Acquisition 
Estrada Carlos Lima Costa Nº2, 2600-009 Vila Franca de Xira Vila Franca de Xira Lisboa PORTUGAL  
33600000-6 - Pharmaceutical products
 
 
 

Scheduling

Scheduling
9/7/2023 11:37 AM (UTC +1 hour)
 
12/23/2020 12:00 AM (UTC 0 hours)
 
9/11/2023 5:00 PM (UTC +1 hour)
 

Financial Settings

Financial Settings
No 
No 

Contract Documents

Contract Documents
Document NameDescriptionDoc Classification
Convite_HVFX_61003123_signed.pdfConvite_HVFX_61003123_signed.pdfDownload
Anexo_IV_Formulario_Resposta_61003123.xlsxAnexo_IV_Formulario_Resposta_61003123.xlsxDownload
CE_2021_6_signed.pdfCE_2021_6_signed.pdfDownload

Object of contract

No 
No 

Legal, economic, financial and technical information

NA 
No 

Questionnaire

Questionnaire
 
 
 1 
Questionário
 1.1  
 Lote 1Section for Lot - O1030 - OCRELIZUMAB [300 MG/ 10 ML; SOL INJ; FRS]
 1.1.1   
Lote 1
Bill of Quantities *
(Os valores indicados não incluem o IVA)
Solicitou requisitos adicionais nesta lista de preços.
     
Preço Total
0,000000
EUR
     
 
Cód. ArtigoReferência InternaDescriçãoQtUnidadePreço UnitárioPreço Total
     
O1030
OCRELIZUMAB [300 MG/ 10 ML; SOL INJ; FRS]
10,000000
UN
 
500233810 | Roche - Farmacêutica Química, Lda. | CPA:2021006/150/0322 | NºAIM:5737523;
  

Public Messages

Public Messages
TypeReferenceSubjectDate
No items found...